At September 30, 2024, Longboard’s cash, cash equivalents and short-term investments were approximately $288.4 million.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LBPH:
- Longboard Pharmaceuticals granted Orphan Drug Designation for bexicaserin
- Longboard Pharmaceuticals Inc options imply 0.8% move in share price post-earnings
- Largest borrow rate increases among liquid names
- Longboard Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright
- Longboard Pharmaceuticals downgraded to Neutral from Buy at B. Riley